Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.

Espinel-Ingroff, A; Chowdhary, A; Gonzalez, G M; Guinea, J; Hagen, F; Meis, J F; Thompson, G R; Turnidge, J

Espinel-Ingroff, A; Chowdhary, A; Gonzalez, G M; Guinea, J; Hagen, F; Meis, J F; Thompson, G R; Turnidge, J.

Afiliação

Espinel-Ingroff A; VCU Medical Center, Richmond, Virginia, USA avingrof@vcu.edu.
Chowdhary A; Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.
Gonzalez GM; Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Guinea J; Hospital General Universitario Gregorio Marañón, School of Medicine-Universidad Complutense, Madrid, Spain.
Hagen F; Department of Medical Microbiology & Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Meis JF; Department of Medical Microbiology & Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Thompson GR; University of California Davis Medical Center, Davis, California, USA.
Turnidge J; University of Adelaide, Adelaide, Australia.

Antimicrob Agents Chemother ; 59(1): 666-8, 2015 Jan.

Article em En | MEDLINE | ID: mdl-25313209

ABSTRACT

ABSTRACT

Epidemiological cutoff values (ECVs) of isavuconazole are not available for Cryptococcus spp. The isavuconazole ECVs based on wild-type (WT) MIC distributions for 438 Cryptococcus neoformans nongenotyped isolates, 870 isolates of genotype VNI, and 406 Cryptococcus gattii isolates from six laboratories and different geographical areas were 0.06, 0.12, and 0.25 µg/ml, respectively. These ECVs may aid in detecting non-WT isolates with reduced susceptibilities to isavuconazole.

Assuntos

Antifúngicos/farmacologia; Cryptococcus gattii/efeitos dos fármacos; Cryptococcus neoformans/efeitos dos fármacos; Nitrilas/farmacologia; Piridinas/farmacologia; Triazóis/farmacologia; Antifúngicos/uso terapêutico; Criptococose/tratamento farmacológico; Cryptococcus gattii/genética; Cryptococcus neoformans/genética; Genótipo; Humanos; Testes de Sensibilidade Microbiana; Nitrilas/uso terapêutico; Piridinas/uso terapêutico; Triazóis/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridinas / Triazóis / Cryptococcus neoformans / Cryptococcus gattii / Antifúngicos / Nitrilas Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google